CD274 and cancer: Given that HNSCC is known to be an immunosuppressive disease that negatively impacts anti-tumor immune responses and considering that the PD-1/PD-L1 interaction is a target of immune checkpoint inhibitors aimed at improving cancer treatment outcomes, they observed that PD-L1 on exosomes was associated with disease progression.